Selexipag治疗肺动脉高压疗效性及安全性的Meta分析

周艳奇; 余更生

doi:10.13201/j.issn.1001-1439.2020.03.016

Selexipag治疗肺动脉高压疗效性及安全性的Meta分析

周艳奇^,,
余更生

- 重庆医科大学附属儿童医院心内科儿童发育疾病研究教育部重点实验室国家儿童健康与疾病临床医学研究中心儿童发育重大疾病国家国际科技合作基地儿科学重庆市重点实验室(重庆, 400014)

详细信息

通讯作者: 周艳奇,E-mail:1602714920@qq.com

中图分类号: R543.2

收稿日期: 2019-10-04

修回日期: 2019-12-20

The efficacy and safety of selexipag in treatment of pulmonary arterial hypertension:A Meta Analysis

ZHOU Yanqi^,,
YU Gengsheng

- Department of Cardiovascular, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Children's Hospital of Chongqing Medical University, Chongqing, P. R China; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China

More Information

Corresponding author: ZHOU Yanqi, E-mail: 1602714920@qq.com

Received Date: 04 October 2019

Revised Date: 20 December 2019

摘要

摘要: 目的:运用Meta分析方法评价selexiapag(参考译名:司来帕格)治疗肺动脉高压(PAH)的临床疗效及安全性。方法:计算机检索中文数据库(中国知网、万方数字化期刊全文库、维普)及英文数据库(PubMed、Cochrane library、Embase),检索时间至2019年9月。符合文献纳入标准的文章由2名研究者独立提取文献数据并行质量评价,随后采用RevMan 5.3软件对效应值进行Meta分析。结局指标为总体病死率及不良事件、6 min步行试验(6MWD)、平均肺动脉收缩压(mPAP)、心脏指数(CI)、肺循环血管阻力(PVR)。结果:最终共纳入9项研究,PAH患者共2 139例。研究结果显示selexiapag治疗PAH可明显提高6MWD(WMD=43.83,95%CI:18.89~73.71,P＜0.05),可有效改善患者病死率(OR=0.72,95%CI:0.57~0.93,P=0.01),可减轻PVR(SMD=-0.66,95%CI:-0.98~0.33,P＜0.05),可明显提高CI(WMD=0.34,95%CI:0.16~0.53,P＜0.05),不能有效降低PAH的mPAP(WMD=-3.26,95%CI:-6.97~0.28,P=0.07),头痛发生率亦明显提高(WMD=0.34,95%CI:0.16~0.53,P＜0.05)。结论:Selexiapag为PAH的安全性药物,在提高6MWD和CI、减轻PVR、改善预后方面有一定疗效,但能否降低平均mPAP还需进一步研究。
- selexipag /
- 肺动脉高压 /
- 临床疗效 /
- Meta分析
Abstract: Objective:A deep meta-analysis was conducted to evaluate the clinical efficacy and safety of selexiapag in the treatment of pulmonary arterial hypertension.Method:Both Chinese database(CNKI,WanFang Data,VIP) and English databases(PubMed,Cochrane Library,EMBASE) up to September 2019 were thoroughly searched.My partner and I extracted data and conducted quality evaluation independently based on journals that have met the standards of our study.Then we used the RevMan5.3 software to perform effect value meta-analysis.The outcome indexes included overall mortality,adverse events,6-minute walking test(6 MWD),mean pulmonary artery systolic pressure(mPAP),cardiac index(CI) and pulmonary vascular resistance(PVR).Result:2 139 PAH patients from 9 studies were involved.The results showed that selexiapag could significantly ameliorate 6 MWD(WMD=43.83,95%CI:18.89—73.71,P＜0.05),improve patient mortality(OR=0.72,95%CI:0.57—0.93,P=0.01),lower pulmonary vascular resistance(SMD=-0.66,95%CI:-0.98—0.33,P＜0.05),and improve cardiac index(WMD=0.34,95%CI:0.16—0.53,P＜0.05).However,selexiapag could neither effectively reduce the average pulmonary arterial pressure of PAH(WMD=-3.26,95%CI:-6.97—0.28,P=0.07),nor effectively reduce the headache incidence(WMD=0.34,95%CI:0.16—0.53,P＜0.05).Conclusion:Selexipag is a safe drug for PAH,it can improve 6 MWD,CI,and lower pulmonary vascular resistance.However,further research should be conducted in the future.
- selexipag /
- pulmonary hypertension /
- clinical efficacy /
- Meta analysis

HTML全文

参考文献(19)

[1]	Santos-Ribeiro D,Mendes-Ferreira P,Maia-Rocha C,et al.Pulmonary arterial hypertension:Basic knowledge for clinicians[J].Arch Cardiovasc Dis,2016,109(10):550-561.
[2]	卢一品,刘宏生.肺动脉高压的发病机制和药物治疗进展[J].临床心血管病杂志,2019,35(2):109-112.
[3]	Galiè N,Humbert M,Vachiery JL,et al.2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension[J].Rev Esp Cardiol (Engl Ed),2016,69(2):177.
[4]	Stang A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J].Eur J Epidemiol,2010,25(9):603-605.
[5]	张天嵩.实用循证医学方法学(第2版)[M].湖南:中南大学出版社,2014:112-114.
[6]	Wan X,Wang W,Liu J,et al.Estimating the sample mean and standard deviation from the sample size,median,range and/or interquartile range[J].BMC Med Res Methodol,2014,14:135.
[7]	Simonneau G,Torbicki A,Hoeper MM,et al.Selexipag:an oral,selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension[J].Eur Respir J,2012,40(4):874-880.
[8]	Sitbon O,Channick R,Chin KM,et al.Selexipag for the Treatment of Pulmonary Arterial Hypertension[J].N Engl J Med,2015,373(26):2522-2533.
[9]	Beghetti M,Channick RN,Chin KM,et al.Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction:insights from the randomised controlled GRIPHON study[J].Eur J Heart Fail,2019,21(3):352-359.
[10]	Coghlan JG,Channick R,Chin K,et al.Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy:Insights from the Randomized Controlled GRIPHON Study[J].Am J Cardiovascu Drugs,2018,18(1):37-47.
[11]	Gaine S,Chin K,Coghlan G,et al.Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension[J].Eur Respir J,2017,50(2).1602493.
[12]	Nobuhiro T,Satoshi I,Nobuhiro T,et al.Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist,Selexipag,in Japanese Patients With Pulmonary Arterial Hypertension[J].Circ J,2017,81(9):1360-1367.
[13]	Frost A,Janmohamed M,Fritz J S,et al.Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension:Results from the TRANSIT-1 study[J].J Heart Lung Transplant,2019,38(1):43-50.
[14]	Berlier C,Schwarz E I,Saxer S,et al.Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension:A Retrospective Analysis[J].Lung,2019,197(3):353-360..
[15]	Barnikel M,Kneidinger N,Klenner F,et al.EXPRESS:Real-life data on Selexipag for the treatment of Pulmonary Hypertension[J].Pulm Circ,2019,9(1):2045894019832199.
[16]	Gabler NB,French B,Strom BL,et al.Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials[J].Circulation,2012,126(3):349-356.
[17]	Pulido T,Adzerikho I,Channick RN,et al.Macitentan and morbidity and mortality in pulmonary arterial hypertension[J].N Engl J Med,2013,369(9):809-818.
[18]	Uthman OA,Yahaya I.Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension[J].Circ J,2010,74(11):2503.
[19]	曾晓春,黄丽蓉,伍伟锋.成人特发性肺动脉高压患者临床特点及预后分析[J].临床心血管病杂志,2018,34(1):42-47.